AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

Chronic myeloid leukemia (CML) represents the first human malignancy successfully treated with a tyrosine kinase inhibitor (TKI; imatinib). However, early relapses and the emergence of imatinib-resistant disease are problematic. Evidence suggests that imatinib and other inhibitors may not effectivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Liang L., Zhao, Yun, Ringrose, Ashley, DeGeer, Donna, Kennah, Erin, Lin, Ann E.-J., Sheng, Guoqing, Li, Xiao-Jiang, Turhan, Ali, Jiang, Xiaoyan
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2008
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571939/
https://www.ncbi.nlm.nih.gov/pubmed/18936234
http://dx.doi.org/10.1084/jem.20072316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571939/
https://www.ncbi.nlm.nih.gov/pubmed/18936234
http://dx.doi.org/10.1084/jem.20072316

Ejemplares similares